Article Per Year (5 Year)
p-Index From 2020 - 2025
5.848
P-Index
This Author published in this journals
All Journal Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Jurnal Kedokteran Brawijaya Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Jurnal Kesehatan Folia Medica Indonesiana Jurnal Farmasi Klinik Indonesia Pharmacon MPI (Media Pharmaceutica Indonesiana) Pharmascience JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Pharmasipha PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) JFIOnline Pharmaceutical Journal of Indonesia JFM (Jurnal Farmasi Malahayati) JURNAL FARMASIMED (JFM) Majalah Farmasetika Jurnal Ilmiah Farmasi Farmasyifa Budapest International Research in Exact Sciences (BirEx Journal) Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Farmasi dan Sains Indonesia (JFSI) Indonesian Journal of Pharmaceutical Education Journal of Global Pharma Technology Journal of Tropical Pharmacy and Chemistry Jurnal Sains dan Kesehatan Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)
Didik Hasmono
Department Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Airlangga
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Education Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Transportation Other

Published : 72 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 72 Documents
Search

 3   4   5   6   7 
Studi pola administrasi penggunaan asetosal pada pasien stroke iskemik Almuhtarihan, Irsan Fahmi; Irianto, Jimmy Setiawan; Hasmono, Didik; Syifa, Nailis'
Pharmasipha : Pharmaceutical Journal of Islamic Pharmacy Vol. 8 No. 1 (2024): Maret
Publisher : University Of Darussalam Gontor

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21111/pharmasipha.v8i1.11623

Abstract

Stroke iskemik disebabkan oleh peristiwa trombotik atau emboli yang menyempitkan arteri sehingga menyebabkan penurunan aliran darah ke otak. Oleh karena itu, terapi antiplatelet digunakan untuk menghambat pembentukan tromboksan. Asetosal dianggap sebagai antiplatet lini pertama dan efektivitasnya sudah diketahui dengan baik, namun masih terdapat kebingungan dalam praktik klinis mengenai dosis optimal untuk pencegahan dan pengobatan stroke. Penelitian ini bertujuan untuk mengetahui pola pemberian asetosal pada pasien stroke iskemik di RSUD dr. RSUD Moh Saleh Probolinggo. Penelitian ini bersifat observasional dengan metode retrospektif pada pasien stroke iskemik pada bulan Januari 2021 sampai dengan Desember 2021. Asetosal digunakan sendiri pada semua pasien (20 pasien). Semua pasien diberikan asetosal 1x80 mg p.o. Peralihan terapi dari clopidogrel (1x75 mg) p.o ke acetosal (1x80 mg) p.o. ditemukan pada satu sampel.
The Effectiveness Of Atorvastatin On Kidney Function In Outpatient Diabetic Nephrophaty Patients Hasmono, Didik; Tanasy, Marledy; Firandi, Adelia; Hartono, Ruddy; Hanum, Putri Safitri
Pharmaceutical Journal of Indonesia Vol. 9 No. 1 (2023)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2023.009.01.1

Abstract

Introduction: Dyslipidemia can damage the kidneys through increased oxidative stress. Statins can be used as adjunctive therapy to standard treatment with ACEIs or ARBs to improve renoprotection. Objective: The study is that to analyze the effectiveness atorvastatin on changes in kidney function in patients diabetic nephropathy. Methods: It was observational study. Samples were taken prospectively from diabetic nephropathy patients receiving atorvastatin at the Interna Polyclinic of the Bhayangkara Hospital Surabaya namely November 2021 – January 2022. Patients aged 18 – 80 years received atorvastatin for ≤3 months before the study was conducted, with GFR stages 3A, 3B, and 4, with mild, moderate, and severe albuminuria degrees. Results: There are several patients which receive ARBs, namely candesartan and ketoacid which can affect the results of the analysis so that different tests are conducted in the three groups, the result shows a significant decrease in BUN values in the sample group which receives additional ketoacid therapy (p <0.05); besides, a decrease in parameters albuminuria in the group with additional 16 mg candesartan therapy which is not significant. Conclusion: The administration atorvastatin alone 20 mg or in combination with candesartan 16 mg and ketoacid on kidney function after 3 months of use can prevent the progression of diabetic nephropathy. Key words: Atorvastatin; Diabetic Nephropathy; Kidney Function
The Effectiveness Of Atorvastatin On Kidney Function In Outpatient Diabetic Nephrophaty Patients Hasmono, Didik; Tanasy, Marledy; Firandi, Adelia; Hartono, Ruddy; Hanum, Putri Safitri
Pharmaceutical Journal of Indonesia Vol. 9 No. 1 (2023)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2023.009.01.1

Abstract

Introduction: Dyslipidemia can damage the kidneys through increased oxidative stress. Statins can be used as adjunctive therapy to standard treatment with ACEIs or ARBs to improve renoprotection. Objective: The study is that to analyze the effectiveness atorvastatin on changes in kidney function in patients diabetic nephropathy. Methods: It was observational study. Samples were taken prospectively from diabetic nephropathy patients receiving atorvastatin at the Interna Polyclinic of the Bhayangkara Hospital Surabaya namely November 2021 – January 2022. Patients aged 18 – 80 years received atorvastatin for ≤3 months before the study was conducted, with GFR stages 3A, 3B, and 4, with mild, moderate, and severe albuminuria degrees. Results: There are several patients which receive ARBs, namely candesartan and ketoacid which can affect the results of the analysis so that different tests are conducted in the three groups, the result shows a significant decrease in BUN values in the sample group which receives additional ketoacid therapy (p <0.05); besides, a decrease in parameters albuminuria in the group with additional 16 mg candesartan therapy which is not significant. Conclusion: The administration atorvastatin alone 20 mg or in combination with candesartan 16 mg and ketoacid on kidney function after 3 months of use can prevent the progression of diabetic nephropathy. Key words: Atorvastatin; Diabetic Nephropathy; Kidney Function
STUDI PENGGUNAAN DEKSAMETASON PADA PASIEN COVID-19 DERAJAT BERAT DENGAN KOMORBID DIABETES MELLITUS Hasmono, Didik; As-Shiddiq, Hasbi; Insyirah Idris, Anissah; Agriawan Sudirman; Hartono, Ruddy; Subhan, Mohammad
Jurnal Kesehatan Vol 16 No 2 (2023): : JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v16i2.28712

Abstract

Administration of Dexamethasone in patients with diabetes needs attention because corticosteroids can increase blood glucose concentrations. Therefore, this study aims to determine the effectiveness of using Dexamethasone in patients with severe COVID-19 and how to regulate blood glucose in patients with severe COVID-19 in patients with comorbid Diabetes Mellitus. Inclusion criteria for severe COVID-19 patients with comorbid Diabetes Mellitus who use Dexamethasone and therapy groups and receive insulin therapy with or without OAD in inpatient installations. The sample data obtained from the patient's medical records were 27 patients who met the inclusion and exclusion criteria consisting of 70% male and 30% female. Dexamethasone dose of 1 x 6 mg iv mostly uses combination therapy A, the duration of administration is 8 days, and has an average length of stay of 13 days. The shortest average length of hospitalization was 12 days for patients receiving dexamethasone with therapy C for 10 days, while therapy B for 5 days had an average hospitalization of 14 days. Administration of Dexamethasone dose of 1 x 6 mg iv is effective in severe COVID-19 patients with comorbid Diabetes Mellitus based on the length of hospitalization, respectively 13 days, 14 days, and 12 days with an improvement in the clinical condition of oxygen saturation by 91%, 100%, 100%; RT-PCR/Rapid Ag became negative 74%, 100%, 100%; improvement of chest x-ray results, namely 83%, 33%, 100%. The effect of glucocorticoid dexamethasone in comorbid Diabetes Mellitus patients is regulated by administering long-acting insulin, rapid-acting insulin, and oral anti-diabetic.
Paxlovid in Kidney Failure: A Review Ardianty, Nonie; Suharjono; Hasmono, Didik
MPI (Media Pharmaceutica Indonesiana) Vol. 6 No. 1 (2024): JUNE
Publisher : Fakultas Farmasi, Universitas Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24123/mpi.v6i1.6486

Abstract

The COVID-19 virus caused a global pandemic that claimed many lives. Various vaccines and drugs are used for COVID-19 both via intravenous and oral routes. Paxlovid is a treatment given orally to patients who experience symptoms and is even considered effective in reducing high-risk COVID-19 virus infections. Kidney failure is a special population that can worsen COVID-19. The purpose of this review article was to determine the effectiveness and safety of using Paxlovid in patients who have comorbid diseases, one of which is kidney failure. The method used in preparing this journal was the PRISMA diagram to select the right articles and Google Scholar, Pubmed, and ScienceDirect as literature sources. Based on the exclusion and inclusion criteria, around 4 studies were obtained that were appropriate to the research topic. Paxlovid may be an important option to reduce the risk of COVID-19 in at-risk patients and unvaccinated patients, moreover, careful consideration of the benefits and risks to patients can be reviewed.
Effectiveness of Antiviral Drugs as Covid-19 Therapy Adelia Firandi; Didik Hasmono
Journal of Tropical Pharmacy and Chemistry Vol. 5 No. 3 (2021): J. Trop. Pharm. Chem.
Publisher : Faculty of Pharmacy, Universitas Mulawarman, Samarinda, Indonesia, 75117, Gedung Administrasi Fakultas Farmasi Jl. Penajam, Kampus UNMUL Gunung Kelua, Samarinda, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25026/jtpc.v5i3.291

Abstract

Introduction: SARS-CoV 2 firstly emerged in China on December 2019 and it was spreading rapidly across the world until now. At this time, there is no vaccine or medication approved by the FDA. However, there are some FDA approved medicines for treating other diseases that can be used for Covid-19 based on tests. This review focuses on therapy efficacy, work mechanism, pharmacokinetic profile, safety, and future perspective. Method: Article review related to therapy on Covid-19 patients, particularly antiviral therapy which was the combination of lopinavir and ritonavir, chloroquine, hydroxychloroquine, remdesivir, and favipiravir. The reviewed relevant articles were observational study, in vitro test, case report, and clinical test. Results: A total of 13 articles met the requirement, 9 articles discussed the result of therapy during the medication of COVID-19 patients, 2 reports of in vitro test, and 2 results of clinical trials. Conclusion: From several studies that had been conducted, remdesivir, combination of lopinavir and ritonavir, as well as favipiravir showed benefits in various clinical studies on Covid-19 patients. Meanwhile, chloroquine and hydroxychloroquine showed limited effects and did not affect the decrease of mortality.
Covid-19 and Its Vaccine Development: A Narrative Review Risa Septinia; Didik Hasmono
Jurnal Sains dan Kesehatan Vol. 3 No. 6 (2021): J. Sains Kes.
Publisher : Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25026/jsk.v3i6.444

Abstract

COVID-19 merupakan penyakit saluran pernapasan yang ditetapkan sebagai pandemi pada Maret 2020 dan disebabkan oleh severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Tingginya penyebaran COVID-19 di seluruh dunia menyebabkan pengembangan vaksin mendesak untuk dilakukan. Oleh karena itu, review ini bertujuan untuk mengkaji tentang COVID-19 dan tantangannya dalam pengembangan vaksin serta mengkaji keamanan, efektivitas, dan immunogenisitas dari platform vaksin-vaksin yang telah mendapatkan izin penggunaan di beberapa negara. Berdasarkan pengalaman infeksi yang pernah terjadi di dunia, vaksin mampu mencegah penyebaran penyakit-penyakit infeksi dan menyelamatkan 23,3 juta nyawa. Terdapat beberapa tantangan yang dihadapi dalam pengembangan vaksin untuk COVID-19, diantaranya mudahnya SARS-CoV-2 bermutasi dan potensi terjadinya antibody-dependent enhancement (ADE) setelah vaksinansi. Berbagai macam platform digunakan dalam perkembangan vaksin COVID-19, baik platform teknologi tradisional (inactivated dan live-attenuated vaccine) maupun teknologi baru (viral vector, protein subunit, dan nucleic acid vaccine). Untuk mencegah penyebaran infeksi SARS-CoV-2, terdapat 10 vaksin yang telah mendapatkan izin penggunaan darurat di beberapa negara. Platform yang digunakan antara lain vaksin mRNA, vektor virus, terinaktivasi, dan vaksin peptida. Vaksin-vaksin tersebut dilaporkan efektif, aman dan dapat ditoleransi dengan baik oleh partisipan dengan derajat efek samping yang timbul adalah ringan hingga sedang. Meskipun kejadian ADE tidak ditemukan dalam semua vaksin tersebut, monitoing terhadap kejadian tersebut harus dilakukan karena berdasar pada pengalaman penggunaan platform inactivated vaccine SARS-CoV sebelumnya, diketahui dapat menimbulkan vaccine-associated enhanced respiratory diseases (VAERD).
Evaluation of Remdesivir in Liver Functions Covid-19 Patients At Bhayangkara H.S Samsoeri Mertojoso Hospital Surabaya Maria Angelia Yoshida; Didik Hasmono; Ruddy Hartono; Mohammad Subkhan
Jurnal Sains dan Kesehatan Vol. 4 No. 5 (2022): J. Sains Kes.
Publisher : Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25026/jsk.v4i5.1120

Abstract

Remdesivir is one of the effective anti-viral drugs used as a Covid-19 therapy at moderate, severe and critical degrees. Side effects that need to be considered in the use of remdesivir is hepatotoxicity. The active metabolite of remdesivir (GS-44152) is thought to play a role in mitochondrial damage in liver cells, inhibiting bile acid transport, and inducing oxidative stress. This study was conducted to evaluate the use of remdesivir associated with changes in liver function SGOT and SGPT. This study was retrospective observation of moderate, severe and critical COVID-19 patients receiving remdesivir with inclusion criteria of all inpatient medical records at Bhayangkara Hospital Surabaya for the period of August 2020-July 2021. The results showed that significant increase of liver enzymes occurred in SGPT (Pre 29 .50; Post 33.50) while in SGOT (Pre 33.00; Post 26.00), enzymes were significantly decreased. The decrease was greater in the SGPT (Pre 69.00; Post 47.00) and SGOT (Pre 56.00; Post 32.00) hepatoprotector groups. The use of remdesivir had no effect on liver function as indicated by an increase in SGPT value and a decrease in SGOT value, both of which were still in the normal range.
The Quantitative and Qualitative Analysis of Antibiotic Use in Bone Fracture Patients in a Public Hospital in Indonesia Atmajani, Wanudya; Hasmono, Didik; Awdisma, Wien Maryati; Isparnadi, Erwien; Ramdani, Dewi
Pharmaceutical Journal of Indonesia Vol. 8 No. 1 (2022)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2022.008.01.8

Abstract

Pendahuluan: Terapi antibiotik profilaksis memiliki peran penting dalam memfasilitasi penyembuhan pasca operasi yang optimal. Penggunaan antibiotik yang tidak tepat di rumah sakit akan meningkatkan biaya terapi dan kejadian infeksi nosokomial mikroorganisme infeksius. Antibiotik profilaksis preoperasi diyakini dapat mengurangi kejadian infeksi tempat pembedahan. Tujuan: Penelitian ini bertujuan untuk mengetahui pola penggunaan antibiotik dan menganalisis penggunaan antibiotik secara kualitatif dengan metode Gyssen dan kuantitatif dengan metode defined daily dose (DDD) pada pasien rawat inap dengan fraktur tulang di Rumah Sakit Umum Haji Surabaya, Indonesia. Metode: Penelitian ini merupakan penelitian observasional deskriptif yang dilakukan terhadap 89 sampel. Data dikumpulkan secara retrospektif melalui rekam medis pada periode Januari-Desember 2019. Data penggunaan antibiotic kemudian dianalisis secara kualitatif dan kuantitatif dengan metode Gyssen dan DDD. Hasil: Pada penelitian ini, antibiotik yang banyak digunakan sebagai antibiotik profilaksis dan terapeutik pada pasien fraktur tulang adalah seftriakson. Analisis kuantitatif menggunakan metode DDD menunjukkan bahwa nilai ceftriaxone adalah 45,6/100 pasien-hari dan cefazoline adalah 3,1/100 pasien-hari. Analisis penggunaan antibiotik pada pasien fraktur tulang dengan menggunakan metode Gyssen menunjukkan bahwa penggunaan antibiotik yang rasional sebanyak 84,3%, penggunaan antibiotik tidak tepat waktu sebanyak 4,5%, dan interval pemberian antibiotik tidak tepat sebanyak 11,2%. Kesimpulan: penggunaan antibiotik pada pasien bedah fraktur sudah tergolong penggunaan antibiotik yang rasional namun penggunaan antibiotik masih melebihi standar WHO. Selanjutnya perlu dilakukan penelitian serupa dengan pengambilan data secara prospektif sehingga dapat mengamati kejadian infeksi luka operasi. Introduction: Prophylactic antibiotic therapy has an important role in facilitating optimal postoperative healing. Inappropriate use of antibiotics in hospitals will increase the cost of therapy and the incidence of nosocomial infections of infectious microorganisms. Preoperative prophylactic antibiotics are believed to reduce the incidence of surgical site infections. Objective: This study aims to determine the pattern of antibiotic use and analyse the use of antibiotics qualitatively by the Gyssen method and quantitatively by the defined daily dose (DDD) method in inpatients with bone fractures at the Haji General Hospital Surabaya, Indonesia. Methods: This study was a descriptive observational study conducted on 89 samples. Data were collected retrospectively through medical records in the period January-December 2019. Antibiotic use data were then analysed qualitatively and quantitatively using the Gyssen and DDD methods. Results: In this study, the antibiotic that was widely used as a prophylactic and therapeutic antibiotic in patients with bone fractures was ceftriaxone. Quantitative analysis using the DDD method showed that the value of ceftriaxone was 45.6/100 patient-days and cefazoline was 3.1/100 patient-days. Analysis of antibiotic use in bone fracture patients using the Gyssen method showed that the rational use of antibiotics was 84.3%, the use of antibiotics was not timely as much as 4.5%, and the interval of antibiotic administration was not appropriate as much as 11.2%. Conclusion: the use of antibiotics in fracture surgery patients is classified as rational use of antibiotics but the use of antibiotics still exceeds WHO standards. Furthermore, it is necessary to conduct a similar study with prospective data collection so that it can observe the incidence of surgical wound infection.
Studi Penggunaan Antidislipidemia Pada Pasien Stroke Iskemik (Penelitian dilakukan di RSUD R.T. Notopuro Sidoarjo) Ilfi Hanna, Az Zahra; Hasmono, Didik; Issaura, Issaura; Syifa, Nailis
Indonesian Journal of Pharmaceutical Education Vol 4, No 3 (2024): September-Desember 2024
Publisher : Jurusan Farmasi Universitas Negeri Gorontalo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37311/ijpe.v4i3.29326

Abstract

Stroke is a neurologic deficit resulting from damage to the brain due to disruption of blood flow that occurs suddenly and rapidly. 87% of strokes are ischemic strokes, caused by a lack of oxygen supply to the brain due to embolism, thrombus or atherosclerosis. Blockage of blood flow will disrupt cell function accompanied by necrosis which can then lead to infarction. Antidyslipidemia is given to all ischemic stroke patients as secondary therapy and prevention of recurrent stroke. The use of Antidyslipidemia in ischemic stroke patients improves lipid abnormalities, reduces the occurrence of coronary heart disease, and improves clinical outcomes. This study aim to describe the use pattern of antidyslipidemia in ischemic stroke patients at RSUD R.T. Notopuro Sidoarjo. The type of this research is observational research with retrospective data collection method for the period October 2023 - December 2023 and then analyzed descriptively. The pattern of antidyslipidemia use is a single use pattern, as many as 78 patterns (99%). The most common single use pattern was given atorvastatin (1 x 20 mg) as many as 66 patients (86%). The combination usage pattern given was atorvastatin (1 x 20 mg) po + fenofibrate (1 x 300 mg). The switching use pattern of atorvastatin (1 x 40 mg)po atorvastatin (1 x 20 mg)po was given to 1 patient.
Co-Authors Adinugraha Amarullah Aghnia Fuadatul Inayah Agriawan Sudirman Agriawan Sudirman Agus Sunarko Agus Sunarko Alfa Frista Arta Alfin Giovani Andilusia, Sindy Ardianty, Nonie Arina Dery Puspitasari Aryani, Dhita Aryani, Dhita Evi Astutik, Widi Atika Putri Kusumaningtyas Atmajani, Wanudya Awdisma, Wien Maryati Ayumuyas, Nur Palestin Ayumuyas, Nur Palestin Ayunda Nur Hidayatiningsih Bambang Sidharta Binti Muzayyanah Budi Suprapti Budiatin, Aniek Setiya Bura, Ursula Dua Klowe Chrysnanda Maryska Claudia Tiffany Dea Ayu Nabilah Dinda Monika Nusantara Ratri Dini Setiya Praja Dini Setiya Praja, Dini Setiya Donsu, Yosefien Christania Elisabeth Kasih Fadlilah, Umul Firandi, Adelia Ganesha T Trengginas Giovani, Alfin Hanum, Putri Safitri Hariyati, Fera Hariyati, Fera Hartono, Ruddy Hasbi As-Shiddiq Hendra Yadi Heni Pujiastuti Hidajah Rachmawati Hidajah Rachmawati Hidayah Karuniawati Hidayah, Ana Nurlaili IGD Ugrasena Ilfi Hanna, Az Zahra Insyirah Idris, Anissah Irianto, Jimmy Setiawan Irsan Fahmi Almuhtarihan Irsan Fahmi Almuhtarihan Ismawati Isparnadi, Erwien Issaura, Issaura Jenggo Suwarko Joko Semedi Junaidi Khotib Khairil Armal Kuntaman Kuntaman Kusumaningtyas, Atika Putri Lilik Yusetyani Lilik Yusetyani Machin, Abdulloh Mahardian Rahmadi Mareta Rindang Andarsari Maria Angelia Yoshida Meiliana, Made Laksmi Meo, Maria Lettisia Mia Melinda Mohammad Saiful Islam Mohammad Subhan Mohammad Subhan Mohammad Subhan Mohammad Subkhan Muhammad Nashrullah Muktamiroh Muktamiroh Nadriatul Utami Nailis Syifa Ni Made Eravikania Putri Darmawan Nun Zairina, Nun Nur Hadiyanti Nuraida Wisudani Nurfausiah, Nurfausiah Nurmainah Nurmainah Nurul Ma'rifah Paulus Sugianto Pharmasinta Putri Hapsari Pramadani, Yana Puri Safitri Hanum Puspitasari, Diny Putri Nurhidayah, Eka Ramdani, Dewi Retna Dwi Puspitarini Rino Wahyudi, Rino Risa Septinia Rizki Lisya Nugraha Roni Subagyo RR. Ella Evrita Hestiandari Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruhaya Fitrina, Ruhaya Samirah Samirah Sandra J. Parambang Sandra, Pipit Semedi, Joko Sendi Lia Yunita Setiawan, Landia Siti Surdijati Siti Surdijati, Siti Sofiati Diah Baisuni Suharjono Suharjono, Suharjono Sumarno Sumarno Syifa', Nailis Syifa, Nailis' Tanasy, Marledy Taufiqur Rahman, Taufiqur Thayyib, Muqoddar Tista Ayu Fortuna Ulfa Syafli Nosa Usman Hadi Utami, Nadriatul Wardhani, Firdha Aprillia Wardhani, Hety Setya Widi Astutik Widi Astutik Wien Maryati Awdisma Wiranata, I Made Worotikan, Natania Imanuella Yosefien Christania Donsu Yudi Agung Wibisono Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani, . Yuni, Santi Eka Yuni, Santi Eka